Compare LGL & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGL | GOSS |
|---|---|---|
| Founded | 1917 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.0M | 83.2M |
| IPO Year | 2017 | 2018 |
| Metric | LGL | GOSS |
|---|---|---|
| Price | $7.20 | $0.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.19 |
| AVG Volume (30 Days) | 12.5K | ★ 15.4M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,169,000.00 | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $201.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.45 | $0.11 |
| 52 Week High | $7.88 | $3.87 |
| Indicator | LGL | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 45.66 |
| Support Level | $6.65 | $0.14 |
| Resistance Level | $7.35 | $0.20 |
| Average True Range (ATR) | 0.28 | 0.02 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 0.00 | 21.40 |
LGL Group Inc is a holding company engaged in services, merchant investment, and manufacturing business activities. The company has two reportable segments: Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications, including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).